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EDITORIAL COMMENT
Can an Energy-Deficient
Heart Grow Bigger and Stronger?*
Robert Roberts, MD, FACC,
Ali J. Marian, MD, FACC
Houston, Texas
Since its initial description by two French pathologists more
than a century ago (1), hypertrophic cardiomyopathy
(HCM), a genetic model of cardiac hypertrophic response
(2), has remained an intriguing disease that has fascinated
clinicians and scientists alike. While it is easy to fathom a
hypertrophic cardiac response to an external stressor, a
myocyte loss, or gross cardiac dysfunction, there is no
increase in external load, no discernible myocyte loss, or no
gross cardiac dysfunction in HCM. Thus, how would one
explain the development of cardiac hypertrophy in HCM?
As early as in 1975, Grossman et al. (3) proposed enhanced
myocardial contractility alone, evidenced by an increased left
ventricular ejection fraction, could be responsible for the
development of cardiac hypertrophy. Accordingly, increased
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contractility, conferred by the underlying genetic defect,
could increase wall stress by shifting the force to an earlier
time point in systole before thickening of the left ventricular
wall (force-thickness mismatch). Increased systolic wall
stress stimulates parallel replication of sarcomeres and hy-
pertrophy. Nevertheless, despite preserved left ventricular
ejection fraction, there is considerable evidence to suggest
myocardial contraction and relaxation in HCM are reduced,
even in the absence of discernible cardiac hypertrophy
(4–6). Thus, alternatively, impaired myocardial contraction
and relaxation could provide the stimulus for the develop-
ment of hypertrophy in HCM. To resolve the apparent
conflicting hypotheses, elucidation of the molecular patho-
genesis of HCM is necessary. Since HCM is a genetic
disease, identification of the primary defect that instigates
the development of cardiac hypertrophy had to await eluci-
dation of the molecular genetic basis of HCM.
The seminal discovery of an arginine to glutamine mu-
tation in amino acid position 403 in the -myosin heavy
chain (MyHC) about 12 years ago in the affected members
of a family with HCM led to elucidation of the molecular
genetic basis of HCM (7). Subsequently, a large number of
mutations in 11 genes encoding sarcomeric proteins were
identified that encompass missense, deletion, and truncation
mutations in the -MyHC, cardiac troponin T (cTnT), and
myosin binding protein-C (MyBP-C), the three most
common causal genes for HCM (2). Today, HCM is a
considered a disease of contractile sarcomeric proteins.
However, since hypertrophy is a common response of the
myocardium to a variety of external and internal stimuli, it
is not surprising that a gross phenotype similar to HCM
(i.e., cardiac hypertrophy in the absence of an increased
external load) could also arise from defects in non-
sarcomeric proteins. Examples are several and include ex-
pansion of trinucleotide repeats in myotonin protein kinase
(myotonic dystrophy) (8) and frataxin (Friedrich’s ataxia)
(9), and mutations in mitochondrial deoxyribonucleic acid
(Kearns Sayre syndrome) (10) and in the 2 subunit of
adenosine monophosphate kinase (11,12). While gross car-
diac phenotype in sarcomeric and non-sarcomeric HCM
appears similar, pathologic phenotype as well as the patho-
genesis of cardiac hypertrophy are expected to differ. This
notion is supported by the results of a recent study of
mutations in 2 subunit of AMP kinase, suggesting cardiac
hypertrophy, due in part at least to storage of glycogen in
the myocardium, is not associated with myocyte or myofi-
brillar disarray, the hallmark of HCM due to defects in
sarcomeric proteins (13). Whether such a pathologic dis-
tinction is a consistent feature of cardiac hypertrophy caused
by mutations in non-sarcomeric proteins remains to be
determined.
Identification of the molecular genetic defects in HCM
was soon followed by a large number of in vivo and in vitro
functional studies with the goal of delineating the primary
defect and, hence, the molecular pathogenesis of HCM
phenotypes. In view of the diversity of the causal mutations,
not surprisingly a diverse array of initial defects was de-
scribed reflective of differences in the function of the causal
proteins and topography of the mutations as well as differ-
ences in the experimental conditions (14). Despite the
wealth of data, a fundamental issue of whether mutations
afford gain-of-function, as one would speculate from the
Grossman et al. (3) hypothesis 27 years ago, or loss-of-
function, as some experimental data would suggest, remains
unsettled. Similarly, whether cardiac myocyte dysfunction
results from impaired contractile performance or altered
calcium homeostasis in the sarcomere or a bioenergetic
deficit also remains to be proven. We have proposed that the
primary structural defect incites a functional defect in the
responsible sarcomeric protein and myocytes leading to
increased myocyte stress (15). Increased myocyte stress,
whether mechanical, biochemical, or bioenergetic leads to
expression and activation of a variety of stress-responsive
molecules and intracellular signaling molecules that insti-
gate gene expression and induction of diverse histological
and structural phenotypes including cardiac hypertrophy,
interstitial fibrosis, and myocyte disarray. The presence and
severity of phenotypic expression are determined not only by
the topography of the causal mutations and their impacts on
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the function of the sarcomeric proteins and myocytes, but
also by the modifier genes as well as non-genetic and
environmental factors (16).
In this issue of the Journal, Crilley et al. (17) provide
evidence suggesting insufficient utilization of adenosine
triphosphate (ATP) in the myocardium of patients with
HCM provides the stimulus for the development of cardiac
phenotype. Evidence for the “energy compromise” in the
myocardium is based on demonstration of a 30% difference
in the resting ratio of cardiac phosphocreatine (PCr) to
ATP between 31 patients with mutations in either the
-MyHC or cTnT or MyBP-C gene and 24 control
subjects. There were no significant differences in the PCr/
ATP ratios among HCM subjects who had -MyHC,
cTnT, or MyBP-C mutations, and there was no significant
correlation between PCr/ATP ratio and the maximum wall
thickness. Another interesting finding of the study was a
reduced PCr/ATP ratio in seven subjects who had the
HCM mutations but did not have echocardiographic or
electrocardiographic evidence of cardiac hypertrophy. The
authors suggest that the underlying defect in HCM due to
sarcomeric mutations is inefficient utilization of ATP,
which increases the cost of force production putting excess
demand to the myocyte and, thus, compensatory cardiac
hypertrophy.
The results of the current study (17) complement the
results of previous studies (18–22), including the presence
of reduced myocardial PCr/ATP ratio in patients with
Friedrich’s ataxia irrespective of the presence or absence of
cardiac hypertrophy (22). The strengths of the present study
(17) are: 1) knowing the specific genetic mutation in each
HCM individual included in the study; 2) inclusion of
mutation carriers without cardiac hypertrophy; and 3) mu-
tations in three major causal genes responsible for HCM are
represented. The findings of reduced PCr/ATP ratio in
those with cardiac hypertrophy is not surprising and has
been shown previously in pathologic cardiac hypertrophy
including fully evolved HCM (18–21), as well as in heart
failure and in myocardial ischemia (23). However, the
finding of a reduced PCr/ATP ratio in subjects with
sarcomeric protein mutations but no discernible cardiac
hypertrophy is novel. This is in accordance with the results
of a previous study (22) in Friedrich’s ataxia of subjects
harboring frataxin mutations with no significant cardiac
hypertrophy but who had abnormal PCr/ATP ratios. These
findings collectively implicate altered myocardial bioener-
getics in the development of cardiac hypertrophy, as pro-
posed by the authors of the present (17) and previous (22)
studies. However, review of data shown in Figure 1 of
Crilley et al. (17) subdues the enthusiasm for the proposed
hypothesis. Despite the mean values being statistically
different, there is a significant overlap in the PCr/ATP ratio
between normal individuals and those with HCM, includ-
ing subjects with causal mutations but no cardiac hypertro-
phy. Table 1 of Crilley et al. (17) shows two possible outliers
in the HCM group that probably account for the major
portion of the differences in the mean values of PCr/ATP
ratios. The presence of a significant degree of overlap in the
PCr/ATP ratio of half of all study subjects shown in Figure
1 of Crilley et al. (17), along with the presence of normal
PCr/ATP ratios in several subjects with HCM, do not
support a direct causal role for myocardial energy deficit in
the pathogenesis of cardiac hypertrophy in HCM. The
absence of a correlation between PCr/ATP levels and the
maximum wall thickness also diminishes the possible con-
tribution of reduced myocardial bioenergetics in affecting
expression of hypertrophic phenotype. In addition, the
potential confounding effects of medications and dietary
supplementation in cardiac high-energy phosphate levels are
unclear. The finding of a reduced PCr/ATP ratio in those
without cardiac hypertrophy raises the possible utility of this
noninvasive technique to detect mutation carriers. Table 1
of Crilley et al. (17) shows 11 of 31 HCM subjects did not
have the pre-defined criteria for left ventricular hypertrophy
(a maximum wall thickness of 13 mm). The PCr/ATP
ratios in seven of these subjects, shown in Figure 1 of Crilley
et al. (17), unfortunately exhibit significant overlap with the
values for the controls. While receiver-operator character-
istics curves are required for the proper analysis, given the
limitations cited in the preceding text, one would expect low
sensitivity for detecting pre-clinical HCM even when re-
stricted to screening family members of affected pro-bands.
Another interesting aspect of the results of the present
study is absence of a significance difference in the PCr/ATP
ratio among HCM patients with mutations in three differ-
ent causal genes, as shown in Figure 1 of Crilley et al. (17).
This finding, along with the observation that hypertrophy of
any cause reduces the PCr/ATP ratio, and heart failure
associated with other causes may have a decreased PCr/
ATP ratio suggest decreased PCr/ATP is a consequence
rather than a primary defect. The authors appropriately
claim that decreased PCr/ATP is a primary defect based on
the observation that decreased PCr/ATP is observed in
individuals with HCM mutations without hypertrophy.
Nevertheless, the significant overlap in the PCr/ATP ratio
between normal individuals and those with HCM makes
this claim less enticing. Secondly, the specific molecular
defects known for some of the mutations are quite diverse,
namely, altered myosin actin binding, altered calcium affin-
ity, and altered adenosinetriphosphatase activity are unlikely
to lead to the same specific primary defect in bioenergetics.
The absence of a significant difference among the three
groups of HCM patients may reflect the relatively small
number of subjects in each group and, hence, the possibility
of a statistical type II error cannot be excluded. While the
PCr/ATP ratio is considered a well-established indicator of
cardiac energy status, data are needed to show how diverse
mutations, located in different domains and different sarco-
meric proteins affect myocardial PCr/ATP ratio and
whether reduced PCr/ATP ratio reflects lower (PCr) or
higher (ATP) concentrations in the myocardium or a
combination of both. The need for further delineation in
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the components of the PCr/ATP ratio is demonstrated by
data in the GLUT4 null mice, whereby an increase in
myocardial PCr/ATP ratio is associated with severe cardiac
hypertrophy but a depressed myocardial function (24). In
addition, since mutant -MyHC protein is also expressed in
slow skeletal muscles of patients with HCM, an energy
deficit in skeletal muscle of these muscles in pre-clinical
stage would be expected, which would be unexpected since
significant number of HCM subjects succumb to sudden
cardiac death during highly competitive sport activities. It
would be also interesting to determine whether PCr/ATP
ratios were different between interventricular septum, site of
predominant hypertrophy, and other walls, or if a gradient
existed between the subendocardium and the epicardium.
Furthermore, HCM patients could suffer from myocardial
ischemia because of a relative capillary paucity as well
thickening of the media of intramural coronary arteries; the
potential confounding effects of myocardial ischemia, a
major determinant of PCr/ATP ratio, deserve to be ex-
plored. Finally, additional studies are needed to characterize
functional and biological significance of changes in different
components of myocardial bioenergetics, such as transport
of creatine to myocytes via creatine transport uptake protein,
production of ATP in the mitochondria through oxidative
phosphorylation, and/or hydrolysis of ATP to ADP and Pi
by the -MyHC during cardiac cycle.
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